In a phase I clinical trial, the safety, tolerability and feasibility of ex vivo TKD/IL-2-stimulated autologous NK cells were proven in 12 patients with advanced tumor stages (colorectal cancer, n = 11; NSCLC, n = 1) [87]. The gene discussed is IL2; the disease is neoplasm.